|
- Renbio DNA Therapeutics Delivering Next-Generation Medicines
Using RenBio’s Make Your Own (MYO) Technology, therapeutic-encoding “bioblueprints” are delivered via modified intramuscular injection, which are then decoded by the muscle cells to produce disease-fighting therapeutics in the patient’s own body
- RenBio Secures Grants for DNA Therapeutics
The Company’s novel, next-generation, proprietary nucleic acid therapeutics platform, called MYO (Make Your Own) Technology™, is designed to deliver DNA medicines encoding for antibody and protein therapeutics
- MYO Technology - Renbio - MYO Technology - Renbio
Our MYO (Make Your Own) Technology is built to revolutionize the state of antibody and protein therapeutics by empowering patients to produce their own medicines In doing so, we are creating radically new therapies that are longer-lasting than those delivered using standard methods
- RenBio with Global Rights for COVID-19 Bispecific Antibody
We focus on novel antiviral antibody therapeutics and an advanced antibody delivery platform RenBio has also signed a license agreement with Columbia University, giving our company the exclusive worldwide development and commercialization rights to a novel bispecific
- RenBio Announces New Awards to Support Continued Development of Its . . .
RenBio, a privately-held, preclinical biotechnology company leveraging its novel, proprietary MYO (Make Your Own) Technology TM platform to deliver next-generation antibody and protein medicines in the form of DNA therapeutics, today announced that it has received funding to evaluate DNA-based delivery of antiviral antibodies for Zika and
- Team - Renbio
Meet RenBio's co-founders David D Ho, MD and Yaoxing Huang, PhD Drs Ho and Huang have collaborated on several successful scientific projects over more than 25 years and have advanced multiple vaccine and antibody candidates from the bench to the bedside
- RenBio attends the Keystone Symposia - Renbio
RenBio had the pleasure of attending the Keystone Symposia on “Next Generation Antibody Therapeutics: From Discovery to Patient” last month Our Director of Research, Marek Drozdz, Ph D , presented a poster showcasing the potential of RenBio’s MYO Technology™ to deliver antibodies and therapeutic proteins in a way that is durable and
- News Events - Renbio
RenBio Secures Grants for DNA Therapeutics; 2017 RenBio’s DARPA-Funded Tech Spotlighted at Meeting; 2018 RenBio featured in Nature OUTLOOK: The genetic shortcut to antibody drugs; 2019
|
|
|